VBI Vaccines Announces Restructuring and Delisting Update

VBI Vaccines (VBIV) has released an update.

VBI Vaccines Inc. has updated stakeholders on its restructuring process, including a granted provisional relief under Chapter 15 and a scheduled court hearing, alongside the news that its shares will be delisted from Nasdaq effective August 8, 2024, without plans to appeal. The company is under legal advisement from several firms and Ernst & Young Inc. has been appointed as Monitor in the CCAA proceedings.

For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.